The peptide crosses the blood-brain barrier and reduces neuroinflammatory markers including activated microglia and astrocytes
The tablets are easy to swallow, which adds to the convenience
The preclinical literature has described effects across multiple pathways, and mechanistic claims are better framed as a family of related observations rather than a settled mechanism
Users who started at 6080mcg without titration report severe hypoglycemic episodes and injection site inflammation that forced protocol discontinuation
Notably, only 3.5 percent of survey respondents were diagnosed with celiac disease
Declarations Authors contributions Designed the paper, selected and prepared the references, prepared the figures, wrote the manuscript: Wright JW Prepared the references, wrote the manuscript: Harding JW Availability of data and materials Not applicable